Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras

Mandaviya interacts with representatives of private medical colleges

Seeks partnership between government and private medical colleges for providing superior medical education

BDR Pharmaceutical launches the first generic to treat Prostate cancer in India

BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.

Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US

All claims against the company in the litigation have now been dismissed.

Eye-Q inaugurates its new facility in Yamunanagar

The new facility will be able to handle four times as many patients as the previous facility.

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.

Searchlight Pharma to acquire Miravo Healthcare

Miravo to remain a Canadian controlled and operated company following closing of the transaction

Lupin receives USFDA approval for Brivaracetam Tablets